IBB vs VXX
iShares Biotechnology ETF vs iPath Series B S&P 500 VIX Short-Term Futures ETN
IBB$170.10
iShares Biotechnology ETF
NASDAQ biotech and pharmaceutical companies.
Expense: 0.44%Yield: 0.23%
VXX$27.90
iPath Series B S&P 500 VIX Short-Term Futures ETN
VIX short-term futures, hedge / speculation.
Expense: 0.89%Yield: 0.00%
Quick take
- • IBB has the lower expense ratio at 0.44% vs 0.89% for VXX.
- • IBB pays a higher dividend yield (0.23%).
Side-by-side metrics
| Metric | IBB | VXX |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.44% | 0.89% |
Dividend yield Trailing 12-month yield. | 0.23% | 0.00% |
AUM Assets under management — bigger funds are typically more liquid. | $7.95B | $414M |
YTD return | 3.10% | 6.04% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.74 | 60.94 |
P/E ratio | 23.72 | — |
Last price | $170.10 | $27.90 |
Inception | — | — |
Issuer | iShares | Barclays |
IBB top holdings
Top holdings · IBB
| AMGN | Amgen Inc | 7.37% |
| GILD | Gilead Sciences Inc | 7.32% |
| VRTX | Vertex Pharmaceuticals Inc | 7.21% |
| REGN | Regeneron Pharmaceuticals Inc | 6.55% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.71% |
| ARGX | argenx SE ADR | 3.33% |
| INSM | Insmed Inc | 2.70% |
| BIIB | Biogen Inc | 2.67% |
| NTRA | Natera Inc | 2.40% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.27% |
Sector breakdown · IBB
Healthcare100.0%
VXX top holdings
Holdings data unavailable for VXX.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $7.9B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.23%. Its largest holding is Amgen Inc (AMGN), which represents 7.4% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About VXX
VXX (iPath Series B S&P 500 VIX Short-Term Futures ETN) is VIX short-term futures, hedge / speculation. Managed by Barclays, the fund carries $414M in assets under management, an expense ratio of 0.89%.